中国学者在PROSPERO平台注册系统评价/Meta分析的现状调查
|
摘要
目的了解中国学者在PROSPERO平台注册系统评价/Meta分析(SR/MA)的现状,以期为提高注册率、注册质量,为最终提高SR/MA质量提供参考。方法检索PROSPERO注册平台,查找由中国学者注册的SR/MA,检索时间截至2014年12月31日。由2名研究员独立筛选文献和提取资料,采用Excel 2013建立数据库,Stata 12.0软件进行统计分析。结果截止2014年12月31日,我国学者在PROSPERO平台共注册了322个SR/MA,注册数量呈逐年递增的趋势,以2014年最多(195个,60.6%);研究类型以干预性研究的SR/MA为主(247个,76.7%);涉及21个系统疾病,SR/MA数最多的系统疾病为肿瘤(65个,20.2%);注册者来自全国26个省(市、自治区),注册单位多为"循证医学中心";半数以上(56.2%)的计划书报告了基金资助情况;合作机构为2个及以上的仅占39.8%。结论我国学者在PROSPERO平台注册的SR/MA增长迅速,但绝对数量仍然较少,存在合作意识薄弱,部分省市、科研机构对注册、发表计划书的认识不够等问题。
Objective To investigate the current status of systematic reviews/meta-analyses(SRs/MAs) registered in PROSPERO by Chinese authors, in order to provide references for improving the registration rate and quality, and finally improve the quality of SRs/MAs. Methods We searched PROSPERO(http://www.crd.york.ac.uk/crdweb/) from inception to December 31, 2014, to identify SRs/MAs registered by Chinese authors. Two reviewers independently screened records and extracted data. Excel 2013 was used for data input and management, and Stata 12.0 software was used for statistical analysis(Stata Corp., College Station, TX, USA). Results A total of 322 SRs/MAs were included. There was an increasing trend in registration number by year, and 60.6% was registered in 2014. The type of SRs/MAs was mainly the interventional(n=247, 76.7%). These SRs/MAs were related to 21 systematic diseases, and cancer ranked the top one(65, 20.2%). The authors distributed in 26 provinces, and majority of authors' institutes were "EvidenceBased Medicine Center". More than half(56.2%) of SRs/MAs were supported by fundings, but only 39.8% of SRs/MAs were performed cooperatively by two or more institutes. Conclusion There is a rapid increase in numbers of SRs/MAs registered in PROSPERO by Chinese authors, but the absolute number is still small. The problems include the weakness of cooperative consciousness and lake of awareness in registering SRs/MAs.
Objective To investigate the current status of systematic reviews/meta-analyses(SRs/MAs) registered in PROSPERO by Chinese authors, in order to provide references for improving the registration rate and quality, and finally improve the quality of SRs/MAs. Methods We searched PROSPERO(http://www.crd.york.ac.uk/crdweb/) from inception to December 31, 2014, to identify SRs/MAs registered by Chinese authors. Two reviewers independently screened records and extracted data. Excel 2013 was used for data input and management, and Stata 12.0 software was used for statistical analysis(Stata Corp., College Station, TX, USA). Results A total of 322 SRs/MAs were included. There was an increasing trend in registration number by year, and 60.6% was registered in 2014. The type of SRs/MAs was mainly the interventional(n=247, 76.7%). These SRs/MAs were related to 21 systematic diseases, and cancer ranked the top one(65, 20.2%). The authors distributed in 26 provinces, and majority of authors' institutes were "EvidenceBased Medicine Center". More than half(56.2%) of SRs/MAs were supported by fundings, but only 39.8% of SRs/MAs were performed cooperatively by two or more institutes. Conclusion There is a rapid increase in numbers of SRs/MAs registered in PROSPERO by Chinese authors, but the absolute number is still small. The problems include the weakness of cooperative consciousness and lake of awareness in registering SRs/MAs.
引文
1 Mc Kenzie JE,Clarke MJ,Chandler J.Why do we need EvidenceBased Methods in Cochrane?Cochrane Database Syst Rev,2015,7:ED000102.
2 Alan C,Richmond K,李萃萃,等.Cochrane协作网:21世纪第一个十年间Cochrane系统评价组内的国际性活动.中国循证医学杂志,2011,11(10):1106-1110.
3 贾文琴,杨克虎,田金徽,等.Cochrane系统评价发表状况调查.中国循证医学杂志,2009,9(6):635-639.
4 孙晓莹,马婧,赵晔,等.Cochrane系统评价现状.中国循证儿科杂志,2013,8(3):237-240.
5 Moher D,Liberati A,Tetzlaf J,et al.Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement.BMJ,2009,339:b2535.
6 Haaland B,Tan PS,de Castro Jr G,et al.Meta-analysis of i rst-line therapies in advanced non-small-cell lung cancer harboring EGFRactivating mutations.J h orac Oncol,2014,9(6):805-811.
7 Lee JK,Hahn S,Kim DW,et al.Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in nonsmall cell lung cancer harboring wild-type epidermal growth factor receptor:A meta-analysis.JAMA,2014,311(14):1430-1437.
8 Lee CK,Wu YL,Ding PN,et al.Impact of Specific Epidermal G r o w t h F a c t o r R e c e p t o r(E G F R)M u t a t i o n s a n d C l i n i c a l Characteristics on Outcomes At er Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer:A Meta-Analysis.J Clin Oncol,2015,33(17):1958-1965.
9 Chien PF,Khan KS,Siassakos D.Registration of systematic reviews:PROSPERO.BJOG,2012,119(8):903-905.
10 Davies S.h e importance of PROSPERO to the National Institute for Health Research.Syst Rev,2012,1:5.
11 杨智荣,詹思延.PROSPERO:为非Cochrane系统评价全新打造的注册平台.中华医学杂志,2012,92(6):422-425.
12 周建国,周权,马虎.Epi Data软件在定量系统评价数据提取中的应用.循证医学,2014,(6):361-362.
13 王佩鑫,李宏田,刘建蒙.无对照二分类资料的Meta分析方法及Stata实现.循证医学,2012,12(1):52-55,64.
14 Booth A,Stewart L.Trusting researchers to use open trial registers such as PROSPERO responsibly.BMJ,2013,347:f5870.
15 Booth A,Clarke M,Dooley G,et al.The nuts and bolts of PROSPERO:an international prospective register of systematic reviews.Syst Rev,2012,1:2.
16 Editors TPM.Best practice in systematic reviews:the importance of protocols and registration.PLo S Med,2011,8(2):e1001009.
17 Kirkham JJ,Altman DG,Williamson PR.Bias due to changes in specii ed outcomes during the systematic review process.PLo S One,2010,5(3):e9810.
18 Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012.CA Cancer J Clin,2015,65(2):87-108.
19 Tian X,Zhou JG,Zeng Z,et al.Cetuximab in patients with esophageal cancer:a systematic review and meta-analysis of randomized controlled trials.Medical Oncology,2015,32(4):127.
20 Zhou JG,Tian X,Wang X,et al.Treatment on advanced NSCLC:platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone?A systematic review and meta-analysis of randomised controlled trials.Med Oncol,2015,32(2):471.
2 Alan C,Richmond K,李萃萃,等.Cochrane协作网:21世纪第一个十年间Cochrane系统评价组内的国际性活动.中国循证医学杂志,2011,11(10):1106-1110.
3 贾文琴,杨克虎,田金徽,等.Cochrane系统评价发表状况调查.中国循证医学杂志,2009,9(6):635-639.
4 孙晓莹,马婧,赵晔,等.Cochrane系统评价现状.中国循证儿科杂志,2013,8(3):237-240.
5 Moher D,Liberati A,Tetzlaf J,et al.Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement.BMJ,2009,339:b2535.
6 Haaland B,Tan PS,de Castro Jr G,et al.Meta-analysis of i rst-line therapies in advanced non-small-cell lung cancer harboring EGFRactivating mutations.J h orac Oncol,2014,9(6):805-811.
7 Lee JK,Hahn S,Kim DW,et al.Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in nonsmall cell lung cancer harboring wild-type epidermal growth factor receptor:A meta-analysis.JAMA,2014,311(14):1430-1437.
8 Lee CK,Wu YL,Ding PN,et al.Impact of Specific Epidermal G r o w t h F a c t o r R e c e p t o r(E G F R)M u t a t i o n s a n d C l i n i c a l Characteristics on Outcomes At er Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer:A Meta-Analysis.J Clin Oncol,2015,33(17):1958-1965.
9 Chien PF,Khan KS,Siassakos D.Registration of systematic reviews:PROSPERO.BJOG,2012,119(8):903-905.
10 Davies S.h e importance of PROSPERO to the National Institute for Health Research.Syst Rev,2012,1:5.
11 杨智荣,詹思延.PROSPERO:为非Cochrane系统评价全新打造的注册平台.中华医学杂志,2012,92(6):422-425.
12 周建国,周权,马虎.Epi Data软件在定量系统评价数据提取中的应用.循证医学,2014,(6):361-362.
13 王佩鑫,李宏田,刘建蒙.无对照二分类资料的Meta分析方法及Stata实现.循证医学,2012,12(1):52-55,64.
14 Booth A,Stewart L.Trusting researchers to use open trial registers such as PROSPERO responsibly.BMJ,2013,347:f5870.
15 Booth A,Clarke M,Dooley G,et al.The nuts and bolts of PROSPERO:an international prospective register of systematic reviews.Syst Rev,2012,1:2.
16 Editors TPM.Best practice in systematic reviews:the importance of protocols and registration.PLo S Med,2011,8(2):e1001009.
17 Kirkham JJ,Altman DG,Williamson PR.Bias due to changes in specii ed outcomes during the systematic review process.PLo S One,2010,5(3):e9810.
18 Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012.CA Cancer J Clin,2015,65(2):87-108.
19 Tian X,Zhou JG,Zeng Z,et al.Cetuximab in patients with esophageal cancer:a systematic review and meta-analysis of randomized controlled trials.Medical Oncology,2015,32(4):127.
20 Zhou JG,Tian X,Wang X,et al.Treatment on advanced NSCLC:platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone?A systematic review and meta-analysis of randomised controlled trials.Med Oncol,2015,32(2):471.